Corrigendum to: Armodafinil as a Potential Pharmacological Treatment for Attention Deficit Hyperactivity Disorder in
Reyna Lamas-Aguilar1, Araceli Diaz-Ruiz1, Luz Navarro2
1Departamento de Neuroquímica, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Ciudad de México, México.
Abstract:
The author has identified an error in the department of the authors in the article titled, Armodafinil as a Potential Pharmacological Treatment for Attention Deficit Hyperactivity Disorder in Adults: A Review", published in Current Neuropharmacology, 2024, 22(11), 1899-1908 [1]. Details of the error and a correction are provided here. ORIGINAL RAÚL MIRANDA-OJEDA3,4 3The Mind Project, Office for Equity, Diversity, Inclusion, and Belonging, Harvard University, Smith Campus Center, Cambridge, Massachusetts, USA; 4Faculty of Medicine, Autonomous University of Mexico State, Toluca de Lerdo, Estado de Mexico, Mexico CORRECTED RAÚL MIRANDA-OJEDA3,4 3Department of Physical Medicine & Rehabilitation, Harvard Medical School, Boston, Massachusetts, United States of America; 4Faculty of Medicine, Autonomous University of the State of Mexico, Av Paseo Tollocan, C. Jesu´s Carranza, Moderna de La Cruz, 50180 Toluca de Lerdo, Mexico Publisher regret the error and apologize to readers.. The original article can be found online at: https://www.benthamscience.com/article/138216.
More Related Videos
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
13:09Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol
Published on: April 1, 2018
Related Concept Videos
01:30Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
01:22Alzheimer's Disease: Treatment
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
01:23Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment